COVID-19 vaccines have been subject to rigorous testing and have been shown to be safe and effective. However, like all new medicines and vaccines, it is important to continue to monitor them.
The Drug Safety Research Unit (DSRU), based in Southampton, has put a call out for people to take part in a research study to collect more evidence about the AstraZeneca COVID-19 vaccine.
This independent study wishes to recruit people who have had the AstraZeneca vaccine, whether they have had problems or no problems after their vaccination. The vaccine manufacturer is funding it.
The DSRU is an independent research organisation that for over 40 years has been making sure medicines used in the UK are safe.
The findings from the study will be presented to the Medicines and Healthcare Regulatory Agency and the vaccine manufacturer and will help inform future vaccine development.
Who can take part?
People who have been given a 1st dose of the AstraZeneca vaccine within the last six weeks.
If you have received a recent text message from St Mary’s Surgery about this trial, you may be eligible.
What will I have to do?
If you are eligible and consent to join the study, you will be asked to complete an enrolment questionnaire, which includes questions about the vaccination and your health.
Then, for up to 18 months, you will be sent a small number of further short questionnaires.
If you experience certain symptoms or conditions following your two vaccines, the DSRU may wish to contact your GP or other healthcare professionals involved in your care. They will only do this with your permission.
How DSRU looks after your personal data?
Taking part in the study is confidential. Any information collected about you during the course of the study will be kept strictly confidential and the DSRU will only use it for purposes related to the research study. None of your personal data will be shared.
Nobody involved in the study will ever have access to your medical records.
Yes I am interested in finding out how I can be involved
You can register your interest or telephone 0800 619 6222 for further information.